We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
The Gut Stuff is a proactive advocate for gut health, educating a substantial community and offering an innovative app in BETA that aims to bridge gaps in the gut health market. With a strong presence in physical products, workplace education, and media, they're positioned to redefine the gut health category and leverage diversified revenue streams for growth during their expansion into the digital realm.
days to go: Expired investment: £321,662
Thalamos is a software solution for completing the Mental Health Act (MHA) forms digitally, across any device. It aims to help those with acute mental illness access care quickly reducing treatment time from 7 days to 27 hours. The company delivers SaaS (Software-as-a-Service) to National Health Service (NHS) Trusts, local authorities and private mental healthcare providers. It also works directly with the UK healthcare regulator, The Care Quality Commission (CQC). Thalamos has over £500,000 of investment raised till date. Pre Covid-19, the company was already working with the CQC and supported them in safely submitting their statutory forms to hospitals across the country. Over 75% of NHS Trusts have received Thalamos' MHA forms in the last 60 days. The company will use 48% of the investment for product development, 20% for customer on-boarding, 16% for business development, and 16% as working capital.

Pitch Rated

78%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £290,278
Please watch the video for more information
days to go: Expired investment: £964,550
EasyGym operates an international, low-cost, fast-growing, big-box gym franchise network. While working with 6 countries and more than 250 sites, easyGym is growing rapidly with its franchise system and cloud-based technology. It is aiming to provide people with access to high-quality gyms that are open 24/7. The company aims to use its recurring revenue to develop a sustainable business platform capable to drive innovation, generate investment value, and support global expansion. With the proceeds, easyGym will build the biggest global fitness network by 2030. 50% of its proceeds will be used to create a corporate hub in London, 17% will be used in Franchise Marketing, and 33% will be used for Technology and Support.
days to go: Expired investment: £828,357
PlusGuidance is an online counselling and therapy platform. PlusGuidance gives users access to hundred of therapists all over the world so you can find your perfect therapist without being restricted by geography.
days to go: Expired investment: £54,690
With support from the founders of Bulldog Skincare, Zoopla and Love Film, VITL's aim is to improve the nation's health by offering vitamin packs that are fully personalised to the customer. VITL uses artificial intelligence to decipher which nutrients a person needs to ensure a healthy lifestyle. Effectively cutting out the cost of a private nutritionist.

Pitch Rated

44%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: £908,950
Cambridge Nutraceuticals develop and sell healthcare supplements that are proven to provide health benefits. Their products ar ecurrently on shelves in a number of the large high street retailers such as Holland & Barrett and Boots.
days to go: Expired investment: £1,077,710
PathCloud aims to assemble the global clinical diagnostics resources and data and make them safely available and helpful. The company has created and tested one of the first scalable clinical diagnostics management platforms. It currently has 20,000 clinicians partner networks and 92 registered clinicians. Additionally, it has a network across 48 counties, has over 100 providers, over 3500 diagnostics tests registered and over 10,000 patients by partner telemedicine networks. These funds will be used to gain a significant portion of diagnostics supplier agreements towards the scaling objective, increase efforts towards the international markets and NHS and pursue telemedicine networks.
days to go: Expired investment: £81,720
Next-generation wellbeing analytics for individuals and organisations – boosts happiness and productivity
days to go: Expired investment: £768,597
Rightangled is a healthcare technology company backed by NHS England & regulated by the Care Quality Commission (CQC). It began its journey as a platform that would enable the use of genetic information within the medical practice, in an accurate, streamlined, and affordable way. It gradually established itself as a healthcare provider for screening and diagnostic services. Its Heart DNA Test project, launched in 2017, is helping patients minimize their cardiac risks and enabling doctors to have a complete risk profile for their patients. The project was appreciated and received funding from NHS England. Its next project, Fitness DNA Test, tapped into the fitness and wellbeing markets. Recently, in the wake of the COVID-19 threat, the company has developed a home-based throat swab test to detect the viral infection, by testing viral load presented in its nucleic acid material within (RNA). For its efforts, Rightangled has been featured on CNN, Sky News, LBC radio, Sky News radio, and Newsweek. With the investment, the company aims to release a mobile application by the end of 2020, and develop an AI system to give instant tailored health, diet, and fitness advice to its users based on the data gathered from patient-doctor interactions and patient responses.

Pitch Rated

81%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £522,689
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph